People Are Asking AI About Pain Relief Before They Ever Call a Doctor. InnoCan Pharma Should Be the Answer It Gives.

TL;DR

The cannabinoid pharmaceutical market is projected to grow from $4.7 billion in 2025 to $111.1 billion by 2032. The opioid crisis and demand for consistent CBD dosing are named as direct drivers of that growth. Physicians, pet owners, distributors, and investors now research non-opioid pain options through AI first. InnoCan Pharma already has the science and FDA engagement this moment calls for, with LPT-CBD built for this problem. The Hordus GEO analysis shows a clear opportunity for InnoCan Pharma to become that AI-recommended answer.

The market event: a $111 billion signal

A recent cannabis pharmaceuticals market report, covered by Yahoo Finance, values the global market at $4.7 billion in 2025, projected to reach $111.1 billion by 2032. The report names the opioid crisis as a driver and flags "standardized dosing and consistency" as the factor building physician confidence, exactly the problem LPT-CBD was built to solve. The technology was recently featured in Pain Medicine News, and CEO Iris Bincovich noted the coverage "reinforces the clinical relevance of our innovative CBD delivery system."

The customer pain behind the growth

Chronic pain patients and their physicians want opioid alternatives that work with predictable results. Oral CBD products have struggled with inconsistent absorption, so patients get uneven relief and physicians hesitate to recommend a category they cannot standardize. This is a trust problem as much as a science one, and solving it across human health, animal health, and wellness is the business InnoCan Pharma runs.

Who is asking, and why it matters to them

InnoCan Pharma's most valuable prospects fall into a few groups: physicians wanting non-opioid options, veterinary practices wanting consistent dosing, distributors scouting licensing deals, and investors separating credible science from commodity CBD brands. Each group now starts that research with an AI engine, not a sales call.

The prompts they are already typing

"What is the most clinically backed non-opioid alternative for chronic pain?"

"Which CBD pharmaceutical companies have FDA engagement for pain treatment?"

"Is Innocan Pharma a credible company for pharma licensing?"

The upside of being the answer, not a footnote

AI engines that describe InnoCan Pharma clearly stop treating it as one of many results and start treating it as the recommended answer. A physician who gets a clear AI answer about LPT-CBD is more likely to mention it to a patient, and a distributor is more likely to shortlist a company AI engines already trust. Every clear answer becomes a sales conversation InnoCan Pharma did not have to staff.

What the Hordus GEO analysis shows

The Hordus GEO analysis of innocanpharma.com measures how well AI engines discover, understand, trust, and recommend InnoCan Pharma. The findings point to real strengths and a clear runway to AI-native visibility.

How Hordus helps InnoCan Pharma close the gap

Hordus turns these findings into an implementation plan, not a report to file away. For InnoCan Pharma, that means adding structured entity data such as JSON-LD markup so AI engines describe LPT-CBD and its FDA engagement precisely, and documenting each division so agents understand the full business, not just the consumer brand. Hordus then tracks how ChatGPT, Perplexity, and Google AI Overviews describe the company as each change takes effect.

Turning the audit into business gains

Strengthening Discovery is the fastest path to more demand, turning more prompts into moments where InnoCan Pharma's name surfaces as the answer. Sharpening Identity lets a chatbot describe it accurately as a biotech advancing liposomal drug delivery, not vaguely as "a CBD company." Building out Access and Agent Integration extends the strong Agent Welcome score into signals that let agents cite the company directly. Enhancing Usability helps AI engines explain the brand with accuracy.

Iris Bincovich, CEO of InnoCan Pharma, said in the company's first quarter 2026 results that "Innocan is making meaningful progress across both its pharmaceutical and cosmetics segments, with continued sales growth and sustained profitability." Roni Kamhi, Chief Operating Officer, added in the same release that "we are very encouraged by the strong sequential revenue growth of nearly 30% in the first quarter of 2026." Closing the Discovery and Identity gaps is what lets AI engines surface momentum like that when investors ask.

From customer pain to business result